Pulmonary hypertension in chronic neonatal lung disease

Paediatric Respiratory Reviews

Volumn 11, Issue 3, 2010, Pages 149-153

  Farquhar, Michael ^a   Fitzgerald, Dominic A ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

"new bronchopulmonary dysplasia"; Chronic neonatal lung disease; Pulmonary hypertension; Treatment

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; SILDENAFIL;

ABDOMINAL PAIN; CHRONIC NEONATAL LUNG DISEASE; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DIZZINESS; DOPPLER ECHOCARDIOGRAPHY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SCREENING; EPISTAXIS; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART CATHETERIZATION; HUMAN; INFLUENZA VACCINATION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG DISEASE; LUNG DYSPLASIA; OUTCOME ASSESSMENT; OXYGEN SATURATION; OXYGEN THERAPY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SIDE EFFECT; VISUAL DISORDER; VOMITING;

CHRONIC DISEASE; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; LUNG DISEASES;

EID: 77955417712     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2010.05.001     Document Type: Review

References (49)

1. Smith V.C., Zupancic J.A., McCormick M.C., et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005, 146:469-473.
2. Maclean J.E., Fitzgerald D.A. A rational approach to home oxygen use in infants and children. Paediatr Respir Rev 2006, 7:215-222.
3. Jobe A.H., Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998, 53:81-94.
4. Fitzgerald D., Evans N., Van Asperen P., et al. Subclinical persisting pulmonary hypertension in chronic neonatal lung disease. Arch Dis Child Fetal Neonatal Ed 1994, 70:F118-F122.
5. De Visser Y., Walther F.J., Laghmani E.H., Boersma H., van der Laarse A., Wagenaar G.T.M. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respiratory Research 2009, 10:30. 10.1186/1465-9921-10-30.
6. ATS Documents. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 2003; 168:356-396.
7. Khemani E., et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007, 120:1260-1269.
8. Stenmark K.R., Abman S.H. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 2005, 67:623-661.
9. Bush A., Busst C.M., Knight W.B., Hislop A.A., Haworth S.G., Shinebourne E.A. Changes in pulmonary circulation in severe bronchopulmonary dysplasia. Arch Dis Child. 1990, 65:739-745.
10. Shennan A.T., Dunn M., Ohlsson A., et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirements in the neonatal period. Pediatrics 1988, 82:527-532.
11. Haworth S.G. The management of pulmonary hypertension in children. Arch Dis Child 2008, 93:620-625.
12. Mourani P.M., Sontag M., Younoszai A., Ivy D., Abman S.H. Clinical Utility of Echocardiogrpahy for the Diagnosis and Management of Pulmonary Vascular Disease in Young Children with Chronic Lung Disease. Pediatrics 2008, 121:317-325.
13. Currie P.J., Seward J.B., Chan K.L., et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985, 6:750-756.
14. Skinner J.R., Stuart A.G., O'Sullivan J., Heads A., Boys R.J., Hunter S. Right heart pressure determination by Doppler in infants with tricuspid regurgitation. Arch Dis Child 1993, 69:216-220.
15. Evans N.J., Archer L.N.J. Doppler assessment of pulmonary artery pressure during recovery from hyaline membrane disease. Arch Dis Child 1991, 66:802-804.
16. Evans N.J., Archer L.N.J. Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease. Arch Dis Child. 1991, 66:6-11.
17. Kosturakis D., Goldberg S.J., Allen H.D., Loebor C. Doppler echocardiographic prediction of pulmonary arterial hypertension in congenital heart disease. Am J Cardiol 1984, 53:1110-1115.
18. Bancalari E., Wilson-Costello D., Iben S.C. Management of infants with bronchopulmonary dysplasia. Early Hum Dev 2005, 81:171-179.
19. Abman S.H., Groothius J.R. Pathophysiology and treatment of bronchopulmonary dysplasia. Current issues. Pediatr Clin North Am 1994, 41:277-315.
20. Tay-Uyboco J.S., Kwiatkowski K., Cates D.B., et al. Hypoxic airway constriction in infants of very low birth weight recovering from moderate to severe bronchopulmonary dysplasia. J Pediatr 1989, 115:456-459.
21. Presberg K.W. Dincer HE Pathophysiology of pulmonary hypertension due to lung disease. Curr Opinion in Pulmonary Medicine 2003, 9:131-138.
22. Abman S.H. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007, 91:283-290.
23. Abman S.H. The dysmorphic pulmonary circulation in bronchopulmonary dysplasia: a growing story. Am J Respir Crit Care Med 2008, 178:114-115.
24. Askie L.M., Henderson-Smart D.J., Irwig L., et al. Oxygen saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003, 349:959-967.
25. Fitzgerald D.A., Massie R.J.H., Nixon G., Jaffe A., Wilson A., Landau L.I., et al. Infants with chronic neonatal lung disease: recommendations for the use of home oxygen therapy. Position Statement from the Thoracic Society of Australia and New Zealand. MJA 2008, 189:578-582.
26. Balfour-Lynn I.M., Field D.J., Gringras P., et al. BTS guidelines for home oxygen in children. Thorax 2009, 64(Suppl 2):ii1-26.
27. Sekar K.C., Duke J.C. Sleep apnea and hypoxemia in recently weaned premature infants with and without bronchopulmonary dysplasia. Pediatr Pulmonol 1991, 10:112-116.
28. Fitzgerald D., Van Asperen P., Leslie G., et al. Higher SaO2 in chronic neonatal lung disease: does it improve sleep?. Pediatr Pulmonol 1998, 26:235-240.
29. Mourani P.M., Ivy D.D., Rosenberg A.A., et al. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr 2008, 152:291-296.
30. Abman S.H. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2002, 87:F15.
31. Kotecha S., Allen J. Oxygen therapy for infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2002, 87:F110-114.
32. Subhedar N.V., Shaw N.J. Changes in pulmonary arterial pressure in preterm infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2000, 82:F243-248.
33. Fitzgerald D.A., Rohlicek C., Gottesman R., Davis G.M. Infants with severe bronchiolitis: Is there a role for inhaled nitric oxide?. J Paed Child Health 2001, 37:64-66.
34. Gray P., Rogers Y. Are infants with bronchopulmonary dysplasia at risk for sudden infant death syndrome?. Pediatr 1994, 93:774-777.
35. Poets C.F., Samuels M.P., Southall D.P. Epidemiology and pathophysiology of apnoea of prematurity. Biol Neonate 1994, 65:211-219.
36. Krishnan U., Krishnan S., Gewitz M. treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008, 1082-1086.
37. Radomski M.W., Palmer R.M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987, 92:639-646.
38. Garg U.C., Hassed A. Nitric oxide generating vasodilators and 8-bromo-guanosine monophosphate inhibits mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989, 83:1774-1777.
39. Finer N.N., Barrington K.J. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2006, 1:CD000509.
40. Weissmann N., Gerigk B., Kocer O., et al. Hypoxia induced pulmonary hypertension: different impact of iloprost, sildenafil and nitric oxide. Respir Med 2007, 101:2125-2132.
41. Erickson S., Reyes J., Bohn D., et al. Sildenafil (Viagra) in Childhood and Neonatal Pulmonary Hypertension. J Am Coll Cardiol 2002, 39(Suppl):S402.
42. Humpl T., Reyes J.T., Holtby H., et al. Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension: Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study. Circulation 2005, 111(24):3274-3280.
43. Karatea A.A., Bush A., Magee A.G. Safety and Efficacy of Sildenafil Therapy in Children With Pulmonary Hypertension. Int J Cardiol 2005, 100(2):267-273.
44. Carter N.J., Keating G.M. Bosentan: In Paediatric Patients with Pulmonary Arterial Hypertension. Pediatr Drugs 2010, 12:63-73.
45. Price L.C., Howard L.S.G.E. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs 2008, 8:171-185.
46. Mathai S.C., Girgis R.E., Fisher M.R., et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007, 29:469-475.
47. Porhownik N.R., Al-Sharif H., Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J 2008, 15:427-430.
48. Fitzgerald D.A. Preventing RSV bronchiolitis in vulnerable infants: role of palivizumab. Paediatr Resp Rev. 2009, 10:143-147.
49. Smith L.C., van Asperen P.P., McKay K.O., Selvadurai H., Fitzgerald D.A. Reduced exercise capacity in children born very preterm. Pediatrics 2008, 122:e287-293.